Blood immune markers before surgery in thyroid cancer versus benign thyroid nodules
Compares blood immune markers in adults having surgery for thyroid nodules.
Plain-language title generated from the registry record
Registry title: Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Key facts
- Where
- Istanbul, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults 18 to 75 years old who are scheduled for planned thyroid surgery because of a thyroid nodule or nodular goiter. A blood sample taken before surgery is studied.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- A thyroid nodule or nodular goiter, with planned thyroid surgery. The final lab result after surgery must show differentiated thyroid cancer (papillary, follicular or oncocytic type) or a benign nodular goiter.
- Earlier treatment
- People using immune-suppressing treatment or steroid treatment through the body cannot join.
- Biomarker or test result
- Thyroid stimulating hormone and free thyroxine must be in the normal lab range on the day of blood sampling.
Main reasons for not taking part
- Graves disease, toxic multinodular goiter, toxic adenoma, or an overactive thyroid of any cause
- Active infection
- Any active cancer that is not in the thyroid
- Autoimmune or inflammatory disease other than Hashimoto thyroiditis
- Pregnancy
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07907432, who can take part
Where in Türkiye
- Marmara University School of Medicine Hospital, Department of General SurgeryIstanbul, TürkiyeContact: Muhammer Ergenç, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Marmara University
- Trial code
- NCT07907432
- Record updated
- 2 November 2026
- Original description
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule proves to be benign.Read full original descriptionShow less
Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule proves to be benign.
Adults scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter are enrolled consecutively before surgery, while the nature of the nodule is still unknown. One additional blood tube is obtained during the routine preoperative blood sampling that is performed for every patient on the day of hospital admission, one day before surgery. No separate venipuncture, no additional test, no additional visit and no change to diagnosis, treatment or follow-up is involved.
Serum interleukin-17A, measured before surgery, is the primary outcome measure. Additional Treg/Th17-related cytokines, the interleukin-17A to interleukin-10 ratio, and systemic inflammatory indices calculated from the same blood draw are secondary outcome measures. Participants are assigned to the differentiated thyroid cancer group or the benign nodular goiter group after surgery, on the basis of the final histopathology report.
Inclusion: Age 18 to 75 years; Scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter; Euthyroid, defined as thyroid stimulating hormone and free thyroxine within the laboratory reference range on the day of blood sampling; Written informed consent; Final histopathology of differentiated thyroid carcinoma of papillary, follicular or oncocytic type (case group), or of benign nodular goiter (control group).
Exclusion: Use of immunosuppressive or systemic corticosteroid therapy; Graves disease, toxic multinodular goiter, toxic adenoma, or hyperthyroidism of any cause; Active infection; Any active non-thyroid malignancy; Systemic autoimmune or inflammatory disease other than Hashimoto thyroiditis; Pregnancy.